Brave Asset Management’s CRISPR Therapeutics CRSP Stock Holding History

Brave Asset Management’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-16,700	Closed	-$794K	–	148
2026 Q1	$794K	Buy	16,700 +4,300	+35%	+$227K	0.19%	58
2025 Q4	$650K	Sell	12,400 -2,000	-14%	-$120K	0.15%	66
2025 Q3	$933K	Buy	14,400 +400	+3%	+$23K	0.23%	49
2025 Q2	$681K	Buy	14,000 +10,500	+300%	+$406K	0.18%	63
2025 Q1	$119K	Buy	3,500 +1,000	+40%	+$42.4K	0.04%	140
2024 Q4	$98.4K	Buy	+2,500	New	+$118K	0.03%	141
2024 Q3	–	Sell	-700	Closed	-$37.8K	–	172
2024 Q2	$37.8K	Hold	700	–	–	0.01%	146
2024 Q1	$47.7K	Sell	700 -4,600	-87%	-$329K	0.01%	150
2023 Q4	$332K	Buy	5,300 +3,300	+165%	+$182K	0.09%	94
2023 Q3	$90.8K	Hold	2,000	–	–	0.03%	131
2023 Q2	$112K	Hold	2,000	–	–	0.03%	131
2023 Q1	$90.5K	Buy	+2,000	New	+$97.1K	0.03%	135

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GSK plc London $602M AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Brave Asset Management's CRSP Position: Q2 2026 in Review

Brave Asset Management reduced its CRISPR Therapeutics (CRSP) stake by 38% in Q2 2026, selling an estimated $358K and leaving 11,234 shares worth $613K. The position accounts for 0.13% of the portfolio, ranked #71.

Brave Asset Management first reported a position in CRSP in Q3 2021 and has held it in 17 quarters since. The position peaked at $946K in Q4 2025. 522 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

Brave Asset Management held 11,234 shares of CRISPR Therapeutics worth $613K as of Q2 2026.
Brave Asset Management sold 6,800 CRISPR Therapeutics shares in Q2 2026, an estimated $358K.
CRISPR Therapeutics made up 0.13% of Brave Asset Management's portfolio in Q2 2026, its #71 holding.
Brave Asset Management first reported a position in CRISPR Therapeutics in Q3 2021 and has held it in 17 quarters since.
Brave Asset Management's CRISPR Therapeutics position peaked at $946K in Q4 2025.
522 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Brave Asset Management's 13F filing for Q2 2026, filed 8 Jul 2026.